Psychosis in elderly patients is a growing clinical concern because psychotic symptoms most frequently occur as noncognitive manifestations of Alzheimer’s disease, as side effects of drug therapy for Parkinson’s disease, or as the primary abnormalities in schizophrenia, and the clinical characteristics of psychosis are distinct for each. In planning antipsychotic pharmacotherapy for elderly patients, age-related pharmacokinetic changes, polypharmacy for comorbid diseases, and concerns about the underlying conditions responsible for the psychotic symptoms must be considered. Traditional antipsychotic agents bind to dopamine receptors and effectively relieve positive schizophrenic symptoms but frequently cause tardive dyskinesia and other extrapyramidal symptoms, a problem for elderly patients, particularly for those with Parkinson’s disease. Atypical antipsychotics bind to dopamine and serotonin receptors, relieving both positive and negative symptoms, and are less likely to cause extrapyramidal symptoms. The authors review common diagnostics associated with psychosis in the elderly and clinical guidelines to selecting antipsychotic pharmacotherapy.
Get full access to this article
View all access options for this article.
References
1.
1. Gilley DW, Wilson RS, Beckett LA, Evans DA. Psychotic symptoms and physically aggressive behavior in Alzheimer’s disease. J Am Geriatr Soc1997; 45(9):1074-1079.
2.
2. Zarit SH, Todd PA, Zarit JM. Subjective burden of husbands and wives as caregivers: a longitudinal study. Gerontologist1986; 26(3):260-266.
3.
3. Schneider LS, Olin JT,Doody RS, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study—clinical global impression of change. The Alzheimer’s Disease Cooperative Study. Alzheimer Dis Assoc Disord1997; 11(suppl 2):S22-S32.
4.
4. Steele C,Rovner B,Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry1990; 147(8):1049-1051.
5.
5. Stern Y, Tang MX, Albert MS, et al. Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA1997; 277(10):806-812.
6.
6. Small GW, Rabins PV, Barry PP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA1997; 278(16):1363-1371.
7.
7. Magni E, Binetti G, Bianchetti A, Trabucchi M. Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol1996; 9:123-126.
8.
8. Chui HC, Lyness SA, Sobel E, Schneider LS. Extrapyramidal signs and psychiatric symptoms predict faster cognitive decline in Alzheimer’s disease. Arch Neurol1994; 51(7):676-681.
9.
9. Daniel DG. Antipsychotic treatment of psychosis and agitation in the elderly. J Clin Psychiatry2000; 61(suppl 14):49-52.
10.
10. Kuzuhara S. Drug-induced psychotic symptoms in Parkinson’s disease. Problems, management and dilemma. J Neurol2001; 248(suppl 3):III28-III31.
11.
11. Stoppe G, Brandt CA, Staedt JH. Behavioural problems associated with dementia: the role of newer antipsychotics. Drugs Aging1999; 14(1):41-54.
12.
12. Zayas EM, Grossberg GT. The treatment of psychosis in late life. J Clin Psychiatry1998; 59(suppl 1):5-12.
13.
13. Sajatovic M. Schizophrenia in the elderly: guidelines for management. Cent Nerv Syst Drugs2000; 13(2):103-115.
14.
14. Targum S. Treating psychotic symptoms in elderly patients. Primary Care Companion J Clin Psychiatry2001; 3:156-163.
15.
15. McDowell I. Alzheimer’s disease: insights from epidemiology. Aging (Milano)2001; 13(3):143-162.
16.
16. Jeste DV, Finkel SI. Psychosis of Alzheimer’s disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry2000; 8(1):29-34.
17.
17. Hebert LE, Beckett LA, Scherr PA, Evans DA. Annual incidence of Alzheimer disease in the United States projected to the years 2000 through 2050. Alzheimer Dis Assoc Disord2001; 15(4):169-173.
18.
18. Bassiony MM, Steinberg MS, Warren A, et al. Delusions and hallucinations in Alzheimer’s disease: prevalence and clinical correlates. Int J Geriatr Psychiatry2000; 15(2):99-107.
19.
19. Zimmer JG, Watson N, Treat A. Behavioral problems among patients in skilled nursing facilities. Am J Public Health1984; 74(10):1118-1121.
20.
20. Wragg RE, Jeste DV. Overview of depression and psychosis in Alzheimer’s disease. Am J Psychiatry1989; 146(5):577-587.
21.
21. Tariot PN, Podgorski CA, Blazina L, Leibovici A. Mental disorders in the nursing home: another perspective. Am J Psychiatry1993; 150(7):1063-1069.
22.
22. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology2000; 54(10):1965-1971.
23.
23. Diagnostic and statistical manual of mental disorders: DSMIVTR. 4th ed. Washington, DC: American Psychiatric Press, 2000.
24.
24. McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology1996; 47(5):1113-1124.
25.
25. St. Clair D. Apolipoprotein E gene in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease. J Neural Transm Suppl1997; 51:161-165.
26.
26. Sweet RA, Kamboh MI, Wisniewski SR, et al. Apolipoprotein E andalpha-1-antichymotrypsin genotypes do not predict time to psychosis in Alzheimer’s disease. J Geriatr Psychiatry Neurol2002; 15:24-30.
27.
27. Peyser CE, Naimark D, Zuniga R, Jeste DV. Psychoses in Parkinson’s disease. Semin Clin Neuropsychiatry1998; 3(1):41-50.
28.
28. Targum SD, Abbott JL. Efficacy of quetiapine in Parkinson’s patients with psychosis. J Clin Psychopharmacol2000; 20(1):54-60.
29.
29. Wolters EC, Berendse HW. Management of psychosis in Parkinson’s disease. Curr Opin Neurol2001; 14(4):499-504.
30.
30. Wolters EC. Intrinsic and extrinsic psychosis in Parkinson’s disease. J Neurol2001; 248(suppl 3):III22-III27.
31.
31. Cummings JL, Trimble MR, Hales RE. Clinical neuropsychiatry. In: Hales RE, Yudofsky SC, Talbott JA, eds. Textbook of psychiatry. Washington, DC: American Psychiatric Press, 1999:1667-1991.
32.
32. Arnulf I, Bonnet AM, Damier P, et al. Hallucinations, REM sleep, and Parkinson’s disease: a medical hypothesis. Neurology2000; 55(2):281-288.
33.
33. Hafner H, ander Heiden W. Epidemiology of schizophrenia. Can J Psychiatry1997; 42(2):139-151.
34.
34. Loranger AW. Sex difference in age at onset of schizophrenia. Arch Gen Psychiatry1984; 41(2):157-161.
35.
35. Harris MJ, Jeste DV. Late-onset schizophrenia: an overview. Schizophr Bull1988; 14(1):39-55.
36.
36. Castle DJ, Murray RM. The epidemiology of late-onset schizophrenia. Schizophr Bull1993; 19(4):691-700.
37.
37. Hafner H, Hambrecht M, Loffler W, et al. Is schizophrenia a disorder of all ages? A comparison of first episodes and early course across the life cycle. Psychol Med1998; 28(2):351-365.
38.
38. Riecher-Rossler A, Loffler W, Munk-Jorgensen P. What do we really know about late-onset schizophrenia? Eur Arch Psychiatry Clin Neurosci1997; 247(4):195-208.
39.
39. Lindamer LA, Lohr JB, Harris MJ, et al. Gender-related clinical differences in older patients with schizophrenia. J Clin Psychiatry1999; 60(1):61-69.
40.
40. Brodaty H, Sachdev P, Rose N, et al. Schizophrenia with onset after age 50 years. I: phenomenology and risk factors. Br J Psychiatry1999; 175:410-415.
41.
41. Rivkin P, Kraut M, Barta P, et al. White matter hyperintensity volume in late-onset and early-onset schizophrenia. Int J Geriatr Psychiatry2000; 15(12):1085-1089.
42.
42. Riecher-Rossler A, Rossler W, Forstl H, Meise U. Late-onset schizophrenia and late paraphrenia. Schizophr Bull1995; 21(3):345-356.
43.
43. Wilder-Willis KE, Shear PK, Steffen JJ, Borkin J. The relationship between cognitive dysfunction and coping abilities in schizophrenia. Schizophr Res2002; 55(3):259-267.
44.
44. Schultz SK, Ho BC, Andreasen NC. Clinical features characterizing young-onset and intermediate-onset schizophrenia. J Neuropsychiatry Clin Neurosci2000; 12(4):502-505.
45.
45. Jeste DV, Harris MJ, Pearlson GD, et al. Late-onset schizophrenia. Studying clinical validity. Psychiatr Clin North Am1988; 11(1):1-13.
47. Devanand DP, Jacobs DM, Tang MX, et al. The course of psychopathologic features in mild to moderate Alzheimer disease. Arch Gen Psychiatry1997; 54(3):257-263.
48.
48. Levy ML, Cummings JL, Fairbanks LA, et al. Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer’s disease. Am J Psychiatry1996; 153(11):1438-1443.
49.
49. Jeste DV, Wragg RE, Salmon DP, et al. Cognitive deficits of patients with Alzheimer’s disease with and without delusions. Am J Psychiatry1992; 149(2):184-189.
50.
50. Morris S, Jeste D. Schizophrenia and other psychotic disorders. In: Ettinger W, ed. Principles of geriatric medicine and gerontology. 4th ed. New York: McGraw-Hill, 1998:1341-1349.
51.
51. Harvey PD. Cognitive impairment in elderly patients with schizophrenia: age related changes. Int J Geriatr Psychiatry2001; 16(suppl 1): S78-S85.
52.
52. Arnold SE, Franz BR, Trojanowski JQ. Elderly patients with schizophrenia exhibit infrequent neurodegenerative lesions. Neurobiol Aging1994; 15(3):299-303.
53.
53. Davidson M, Harvey P, Welsh KA, et al. Cognitive functioning in late-life schizophrenia: a comparison of elderly schizophrenic patients and patients with Alzheimer’s disease. Am J Psychiatry1996; 153(10):1274-1279.
54.
54. Jeste DV. Tardive dyskinesia in older patients. J Clin Psychiatry2000; 61(suppl 4):27-32.
55.
55. Jeste DV, Rockwell E, Harris MJ, et al. Conventional vs. newer antipsychotics in elderly patients. Am J Geriatr Psychiatry1999; 7(1):70-76.
56.
56. Mintzer J, Burns A. Anticholinergic side effects of drugs in elderly people. J R Soc Med2000; 93(9):457-462.
57.
57. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry2002; 63(suppl 4):12-19.
58.
58. Maixner SM, Mellow AM, Tandon R. The efficacy, safety, and tolerability of antipsychotics in the elderly. J Clin Psychiatry1999; 60(suppl 8):29-41.
59.
59. Byerly MJ, Weber MT, Brooks DL, et al. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs Aging2001; 18(1):45-61.
60.
60. Masand PS. Side effects of antipsychotics in the elderly. J Clin Psychiatry2000; 61(suppl 8):43-51.
61.
61. Black DW, Andreasen NC. Schizophrenia, schizophreniform disorder, and delusional (paranoid) disorders. In: Hales RE, Yudofsky SC, Talbott JA, eds. Textbook of psychiatry. Washington, DC: American Psychiatric Press, 1999:425-477.
62.
62. van de Vijver DA, Roos RA, Jansen PA, et al. Use of antipsychotics in Parkinson’s disease in daily practice. Br J Clin Pharmacol2002; 53(5):551P-551P.
63.
63. Sultzer DL, Gray KF, Gunay I, et al. Does behavioral improvement with haloperidol or trazodone treatment depend on psychosis or mood symptoms in patients with dementia? J Am Geriatr Soc2001; 49(10):1294-1300.
64.
64. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psychiatry2002; 159(3):460-465.
65.
65. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc2001; 49(12):1590-1599.
66.
66. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology2000; 54(12):2269-2276.
67.
67. Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology2001; 57(4):613-620.
69. Salzman C, Tune L. Neuroleptic treatment of late-life schizophrenia. Harv Rev Psychiatry2001; 9(2):77-83.
70.
70. Sandyk R, Awerbuch GI. Late-onset schizophrenia: relationship to awareness of abnormal involuntary movements and tobacco addiction. Int J Neurosci1993; 71(1-4):9-19.
71.
71. Molho ES, Factor SA. Parkinson’s disease: the treatment of drug-induced hallucinations and psychosis. Curr Neurol Neurosci Rep2001; 1(4):320-328.
72.
72. Katz IR, Jeste DV, Mintzer JE, et al. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry1999; 60(2):107-115.
73.
73. de Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology1999; 53(5):946-955.
74.
74. Davis JM, Chen N. Clinical profile of an atypical antipsychotic: risperidone. Schizophr Bull2002; 28(1):43-61.
75.
75. Barak Y. No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. J Clin Psychiatry2002; 63(2):117-119.
76.
76. Street JS, Clark WS, Gannon KS, et al. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry2000; 57(10):968-976.
77.
77. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a doubleblind, placebo-controlled study of fluoxetine addition. Am J Psychiatry2002; 159(6):1058-1060.
78.
78. Simpson MM, Goetz RR, Devlin MJ, et al. Weight gain and antipsychotic medication: differences between antipsychoticfree and treatment periods. J Clin Psychiatry2001; 62(9):694-700.
79.
79. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry2002; 63(5):425-433.
80.
80. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology2000; 55(6):789-794.
81.
81. Kasper S, Muller-Spahn F. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother2000; 1(4):783-801.
82.
82. Juncos JL. Management of psychotic aspects of Parkinson’s disease. J Clin Psychiatry1999; 60(suppl 8):42-53.
83.
83. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug-induced psychosis in Parkinson’s disease. Mov Disord1999; 14(3):484-487.
84.
84. Tariot P, Schneider L, Katz I, et al. Quetiapine in nursing home residents with Alzheimer’s dementia and psychosis. Paper presented at: 15th Annual Meeting of the American Association of Geriatric Psychiatry; February 24-27, 2002; Orlando, FL.
85.
85. Green B. Focus on ziprasidone. Curr Med Res Opin2001; 17(2):146-150.
86.
86. Bagnall A, Lewis RA, Leitner ML. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database Syst Rev2000; 4.CD001945-CD001945.
88. Schmidt AW, Lebel LA, Howard HR, Jr., Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol2001; 425(3):197-201.
89.
89. Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs2002; 62(8):1217-1251.
90.
90. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry2001; 158(11):1774-1782.
91.
91. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother2002; 36(5):839-851.
